Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study

: Brosseron, Frederic; Kolbe, Carl-Christian; Santarelli, Francesco; Carvalho, Stephanie; Antonell, Anna; Castro-Gomez, Sergio; Tacik, Pawel; Namasivayam, Aishwarya Alex; Mangone, Graziella; Schneider, Reinhard; Latz, Eicke; Wüllner, Ullrich; Svenningsson, Per; Sánchez-Valle, Raquel; Molinuevo, José Luis; Corvol, Jean-Christophe; Heneka, Michael T.; Hofmann-Apitius, Martin; Springstubbe, Stephan; Fröhlich, Holger et al.

Postprint urn:nbn:de:0011-n-6143921 (8.3 MByte PDF)
MD5 Fingerprint: 0a5efcac3ac2944787684069dbe91a2e
(CC) by-nc-nd
Created on: 24.11.2020

Alzheimer's & dementia 16 (2020), No.2, pp.292-304
ISSN: 1552-5260
ISSN: 1552-5279
Journal Article, Electronic Publication
Fraunhofer SCAI ()
Alzheimer's disease; Parkinson's disease; mild cognitive impairment; cerebrospinal fluid; Biomarker; inflammation; amyloid; tau; aging; multicenter

Introduction: Multiple immunity biomarkers have been suggested as tracers of neuroinflammation in neurodegeneration. This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease (PD) subjects from the network of the European, Innovative Medicines Initiative-funded project AETIONOMY.
Methods: A total of 227 samples from the studies/centres AETIONOMY, ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF. Results were compared to data of an independent cohort of 399 subjects previously published.
Results: Immunity markers were predominantly and reproducibly associated with pathological levels of tau isoforms, but also with amyloid levels, aging, sex, APOE genotype, and center-specific factors.
Discussion: Immunity biomarker levels in CSF reflect molecular and cellular pathology rather than diagnosis in neurodegenerative disorders. Assay standardization and stratification for age and other covariates could improve the power of such markers in clinical applications or intervention studies targeting immune responses in neurodegeneration.